A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects With Nonalcoholic Steatohepatitis (NASH)

Purpose of this study is to assess the effects of pemvidutide on NASH resolution and NASH fibrosis.

开始日期2023-07-27

申办/合作机构

Altimmune, Inc.

NCT05295875

/ Completed临床2期

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM Trial)

This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.

开始日期2022-03-31

申办/合作机构

Altimmune, Inc.

NCT05292911

/ Completed临床1期

A 12-Week Extension Study of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

This extension study will assess the safety and effects of 24 weeks of treatment with ALT-801 in diabetic and non-diabetic subjects with overweight and obesity and non-alcoholic fatty liver disease (NAFLD).

开始日期2022-03-09

申办/合作机构

Altimmune, Inc.

100 项与 Pemvidutide 相关的临床结果

登录后查看更多信息

100 项与 Pemvidutide 相关的转化医学

登录后查看更多信息

100 项与 Pemvidutide 相关的专利（医药）

登录后查看更多信息

项与 Pemvidutide 相关的文献（医药）

2025-01-01·JOURNAL OF HEPATOLOGY

Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study

Article

作者: Browne, Sarah K ; Harrison, Stephen A ; Gutierrez, Julio A ; Roberts, M Scot ; Suschak, John J ; Harris, M Scott ; Yang, Jay ; Tomah, Shaheen

BACKGROUND & AIMS:

This was a randomized, double-blind, placebo-controlled study to assess the effects of pemvidutide, a glucagon-like peptide-1 (GLP-1)/glucagon dual receptor agonist, on liver fat content (LFC) in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD).

METHODS:

Patients with a BMI ≥28.0 kg/m² and LFC ≥10% by magnetic resonance imaging-proton density fat fraction were randomized 1:1:1:1 to pemvidutide at 1.2 mg, 1.8 mg, or 2.4 mg, or placebo administered subcutaneously once weekly for 12 weeks. Participants were stratified according to a diagnosis of type 2 diabetes mellitus. The primary efficacy endpoint was relative reduction (%) from baseline in LFC after 12 weeks of treatment.

RESULTS:

Ninety-four patients were randomized and dosed. Median baseline BMI and LFC across the study population were 36.2 kg/m² and 20.6%; 29% of patients had type 2 diabetes mellitus. At week 12, relative reductions in LFC from baseline were 46.6% (95% CI -63.7 to -29.6), 68.5% (95% CI -84.4 to -52.5), and 57.1% (95% CI -76.1 to -38.1) for the pemvidutide 1.2 mg, 1.8 mg, and 2.4 mg groups, respectively, vs. 4.4% (95% CI -20.2 to 11.3) for the placebo group (p <0.001 vs. placebo, all treatment groups), with 94.4% and 72.2% of patients achieving 30% and 50% reductions in LFC and 55.6% achieving normalization (≤5% LFC) at the 1.8 mg dose. Maximal responses for weight loss (-4.3%; p <0.001), alanine aminotransferase (-13.8 IU/L; p = 0.029), and corrected cT1 (-75.9 ms; p = 0.002) were all observed at the 1.8 mg dose. Pemvidutide was well-tolerated at all doses with no severe or serious adverse events.

CONCLUSIONS:

In patients with MASLD, weekly pemvidutide treatment yielded significant reductions in LFC, markers of hepatic inflammation, and body weight compared to placebo.

IMPACT AND IMPLICATIONS:

Metabolic dysfunction-associated steatotic liver disease, and its progressive form steatohepatitis, are strongly associated with overweight/obesity and it is believed that the excess liver fat associated with obesity is an important driver of these diseases. Glucagon-like peptide-1 receptor (GLP-1R) agonists elicit weight loss through centrally and peripherally mediated effects on appetite. Unlike GLP-1R agonists, glucagon receptor agonists act directly on the liver to stimulate fatty acid oxidation and inhibit lipogenesis, potentially providing a more potent mechanism for liver fat content reduction than weight loss alone. This study demonstrated the ability of once-weekly treatment with pemvidutide, a dual GLP-1R/glucagon receptor agonist, to significantly reduce liver fat content, hepatic inflammatory activity, and body weight, suggesting that pemvidutide may be an effective treatment for both metabolic dysfunction-associated steatohepatitis and obesity.

CLINICAL TRIAL NUMBER:

NCT05006885.

2011-12-15·Clinical cancer research : an official journal of the American Association for Cancer Research1区 · 医学

Phase I Trial of ALT-801, an Interleukin-2/T-Cell Receptor Fusion Protein Targeting p53 (aa264–272)/HLA-A*0201 Complex, in Patients with Advanced Malignancies

1区 · 医学

Article

作者: Wong, Hing C. ; Thompson, John A. ; Diez, Luz M. ; Huang, Bee Y. ; Fishman, Mayer N. ; Tang, Shamay ; Daud, Adil I. ; Pennock, Gregory K. ; Rhode, Peter R. ; Weber, Jeffery S. ; Gonzalez, Rene

Abstract:

Purpose: ALT-801 is a bifunctional fusion protein comprising interleukin-2 (IL-2) linked to a soluble, single-chain T-cell receptor domain that recognizes a peptide epitope (aa264–272) of the human p53 antigen displayed on cancer cells in the context of HLA-A*0201 (p53+/HLA-A*0201). We evaluated the safety, pharmacokinetics, and pharmacodynamics of ALT-801 in p53+/HLA-A*0201 patients with metastatic malignancies.Experimental Design: p53+/HLA-A*0201 patients were treated with ALT-801 on a schedule of four daily 15-minute intravenous infusions, then 10 days rest and four more daily infusions. Cohorts of patients were treated at 0.015, 0.040, and 0.080 mg/kg/dose.Results: Four, 16, and 6 patients were treated at the 0.015, 0.04, and 0.08 mg/kg cohorts, respectively. Two dose-limiting toxicities (a grade 4 transient thrombocytopenia and a myocardial infarction) in the 0.08 mg/kg cohort established the maximum tolerated dose (MTD) at 0.04 mg/kg. Patients treated at the MTD experienced toxicities similar to those associated with high-dose IL-2 but of lesser severity. The serum half-life of ALT-801 was 4 hours and ALT-801 serum recovery was as expected based on the dose administered. ALT-801 treatment induced an increase of serum IFN-γ but not TNF-α. Response assessment showed 10 subjects with stable disease at at least 11 weeks, and in one who had melanoma metastasis, there is an ongoing complete absence of identifiable disease after resection of radiographically identified lesions.Conclusion: This first-in-man study defines an ALT-801 regimen that can be administered safely and is associated with immunologic changes of potential antitumor relevance. Clin Cancer Res; 17(24); 7765–75. ©2011 AACR.

Scientific reports3区 · 综合性期刊

Effects of ALT-801, a GLP-1 and glucagon receptor dual agonist, in a translational mouse model of non-alcoholic steatohepatitis

3区 · 综合性期刊

ArticleOA

作者: Nestor, John J ; Feigh, Michael ; Harris, M Scott ; Suschak, John J ; Parkes, David

Abstract:

Body weight loss of ≥ 10% improves the metabolic derangements and liver disease in the majority of non-alcoholic steatohepatitis (NASH) patients, suggesting metabolic modulators may be effective in controlling disease. The pharmacodynamics of ALT-801, a GLP-1/glucagon receptor dual agonist optimized for NASH and weight loss, were compared to semaglutide (GLP-1 receptor agonist) and elafibranor (peroxisome proliferator-activated receptor, PPAR-α/δ, agonist) in a biopsy-confirmed, diet-induced obese (DIO) mouse model of NASH (DIO-NASH). Male C57BL/6J mice were fed Amylin Liver NASH (AMLN) diet for 32 weeks. Animals with biopsy-confirmed steatosis and fibrosis received ALT-801, semaglutide, elafibranor, or vehicle daily for 12 weeks while maintained on the AMLN diet. Study endpoints included body and liver weight, liver and plasma total cholesterol and triglycerides, plasma aminotransferases, histological analysis of liver steatosis, inflammation (galectin-3) and fibrosis (collagen type 1 alpha 1), and evaluation of individual animal changes in composite Non-alcoholic Fatty Liver Disease Activity Score (NAS), and fibrosis stage. ALT-801 demonstrated significant reductions in body weight (approx. 25%), plasma aminotransferases, plasma total cholesterol and liver triglycerides/total cholesterol in conjunction with improved liver steatosis, with greater reductions (p < 0.05) compared to semaglutide and elafibranor. ALT-801 significantly reduced the inflammation marker galectin-3 and the fibrosis marker collagen type 1 alpha 1 vs. vehicle (p < 0.05), with ALT-801 producing greater reductions in galectin-3 vs. elafibranor (p < 0.05). Importantly, all animals treated with ALT-801 significantly improved composite NAS compared to the active controls. This study provides evidence for a potential role for ALT-801 in the therapeutic treatment of NASH.

145

项与 Pemvidutide 相关的新闻（医药）

2024-12-19

·ir.altimmune.com

Altimmune Added to Nasdaq Biotechnology Index

GAITHERSBURG, Md., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) effective prior to the market open on Monday, December 23, 2024. “Our addition to the NBI is an important recognition to conclude what has been a year of major progress for the Company,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “With a number of significant inflection points coming in 2025, including the topline data from the Phase 2b IMPACT trial of pemvidutide in MASH in the second quarter, we believe that we are well positioned heading into the new year.” Established in 1993, the Nasdaq Biotechnology Index is designed to track the performance of a set of Nasdaq-listed securities that are classified as either Biotechnology or Pharmaceutical according to the Industry Classification Benchmark (ICB). Companies in the NBI must meet certain eligibility requirements, including market capitalization, average daily trading volume and seasoning. The Index is evaluated annually and serves as the basis for the iShares NASDAQ Biotechnology Index Fund (Nasdaq: IBB). For more information about the NASDAQ Biotechnology Index, visit: https://indexes.nasdaqomx.com/Index/Overview/NBI. About Pemvidutide Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, which is believed to lead to rapid reductions in levels of liver fat and serum lipids. In clinical trials to date, once-weekly pemvidutide has demonstrated compelling weight loss with class-leading lean mass preservation, and robust reductions in triglycerides, LDL cholesterol, liver fat content and blood pressure. The U.S. FDA has granted Fast Track designation to pemvidutide for the treatment of MASH. Pemvidutide recently completed the MOMENTUM Phase 2 obesity trial and is being studied in the ongoing IMPACT Phase 2b MASH trial. About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com. Follow @Altimmune, Inc. on LinkedIn Follow @AltimmuneInc on Twitter Company Contact: Greg Weaver Chief Financial Officer Phone: 240-654-1450 ir@altimmune.com Investor Contact: Lee Roth Burns McClellan Phone: 646-382-3403 lroth@burnsmc.com Media Contact: Danielle Cantey Inizio Evoke, Biotech Phone: 619-826-4657 Danielle.cantey@inizioevoke.com This press release was published by a CLEAR® Verified individual. Source: Altimmune, Inc

临床2期快速通道临床结果

2024-12-16

·创药网

GLP-1/GCG双重受体激动剂研究进展

GLP-1受体激动剂因其独特的作用优势在降糖及减重领域的研究日趋火热。为追求更好的疗效及更低的药物副作用，以GLP-1为基础的单分子多重受体激动剂有望将几种胃肠激素的有益作用整合到同一个分子中，以改善代谢紊乱。本文着重介绍GLP-1/GCG双重受体激动剂的研究进展，为研发人员提供参考。代谢性疾病如肥胖和糖尿病等具有并发性和异质性的特点，单一药物、单一靶标的治疗方案的疗效有限，通过在单一疗法中组合多种代谢通路，则可能实现多重作用以改善疗效。然而，基于多药组合复方给药的方式，药物开发和临床研究历程相对复杂。因此，设计并获得单个药物分子在多种受体上具备适当平衡的活性成为最佳选择。与共同施用单一激动剂相比，单分子多重受体激动剂因不同信号通路可被同时激活，从而具有疗效最大化、副作用降低、药动学性质更稳定等优点。研究表明，胰高血糖素样肽-1受体（GLP-1R）激动剂与其他不同的胃肠激素共同给药显示出促进或协同作用，从而改善血糖控制和减轻体质量。目前，许多以胰高血糖素样肽-1（GLP-1）为基础的、联合其他胃肠激素发挥促进或协同作用的单分子多重受体激动剂正处于临床前和临床开发阶段，且已表现出协同增效、提高耐受性和改善安全性等益处。以GLP-1为基础的单分子多重受体激动剂主要有五类，包括GLP-1/胃抑制肽（GIP）受体激动剂、GLP-1/胰高血糖素（GCG）受体激动剂、GLP-1/GIP/GCG受体激动剂、GLP-1/GCG/FGF21（人成纤维细胞生长因子21）三重激动剂和GLP-1/GIP/IGF-1（胰岛素样生长因子1）/GCG受体激动剂。下文详细介绍各类多重受体激动剂的研发管线及代表药物研究进展，为肥胖、糖尿病等疾病的治疗提供新思路。 GLP-1/GCG双重受体激动剂 GCG是在胰腺中产生胃肠激素，主要作用与胰岛素相反，响应于空腹或急性低血糖，通过刺激肝脏糖异生和糖原分解升高血糖。同时，GCG能够影响机体代谢和产热过程。研究表明，外源性给予GCG能够减少肝脏三酰甘油（TG）合成并促进肝脂解。GCG的促分解代谢作用和机体产热增加作用对肥胖患者有益。此外，急性给予GCG能适度减少食物摄入。GLP-1和GCG的双重受体激动剂将GCG的产热和脂解作用与GLP-1的延缓胃排空作用相结合以产生显著的体质量减轻作用，并通过GLP-1的促胰岛素分泌作用缓冲GCG的升血糖作用，从而有效控制血糖。据统计，目前研发管线中GLP-1/GCG受体激动剂共计33个（图1），涉及的适应症包括糖尿病、肥胖、高尿酸血症、肝硬化、肝纤维化、非酒精性脂肪性肝炎等。其中，礼来的玛仕度肽（Mazdutide）进展最快，用于2型糖尿病、肥胖、肾功能不全、高尿酸血症的治疗，目前针对2型糖尿病和肥胖处于上市申请阶段；Zealand Pharma的Survodutide处于Ⅲ期临床阶段。另有6个药物进入Ⅱ期临床，2个进入Ⅰ期临床，多个药物处临床前（7个）、发现（3个）、暂停（1个）、无进展（8个）和终止阶段（4个）。图1：全球GLP-1/GCG受体激动剂研发管线玛仕度肽玛仕度肽是研究进展最快的GLP-1/GCG受体激动剂，目前处于上市申请阶段。在激动GLP-1受体实现降糖减重的基础上，玛仕度肽更进一步，通过同时激动GCG受体（GCGR）直接作用肝脏并燃烧内脏脂肪，同时提高全身脂肪组织的能量消耗，由内而外减重并实现降压、降脂、降尿酸等全面代谢获益，每周一次，有望一站式解决代谢患者难题。玛仕度肽预计明年在中国上市，先后获批减重和降糖双适应症。此前，玛仕度肽已在中国人群中探索9mg剂量的减重疗效及代谢获益，研究结果表明，9mg玛仕度肽治疗24周、48周后，与安慰剂相比体重较基线分别下降15.36%、18.55%。当前，玛仕度肽高剂量减重研究全球I期临床研究已完成，玛仕度肽16mg治疗20周减重约20%，表现优异。减重之外，玛仕度肽在代谢综合获益方面更值得期待。改善脂肪肝更明显，激活肝脏GCGR，促进脂肪酸氧化和脂肪分解，Ⅲ期临床结果显示，肝脏脂肪含量降幅80.2%，优于GLP-1R单激动剂和其他双靶激动剂。 Survodutide Survodutide是由Zealand Pharma研发的一种合成多肽，是一种GLP-1/GCG受体激动剂。目前该药物最高研发阶段为Ⅲ期临床，用于治疗肝硬化、非酒精性脂肪性肝炎、糖尿病、超重、肥胖和2型糖尿病。研究已证明，Survodutide在减重方面具有显著效果，在一项多中心Ⅱ期试验中（NCT04667377），针对超重或肥胖且无糖尿病的人群，Survodutide在46周治疗后平均体重减少高达18.7%（基线患者平均BMI为37.1kg/m2）。Survodutide不仅能够显著减轻体重，还能够改善多个心血管代谢参数，包括血压、腰围及血脂水平。此外，GLP-1/GCG受体激动剂可能比单独使用GLP-1受体激动剂在治疗代谢功能障碍相关的脂肪性肝炎（MASH）方面更有效。2024年2月，Survodutide一项针对MASH和肝纤维化患者的Ⅱ期剂量探索性试验的结果发表在了The New England Journal of Medicine上。在治疗48周后，相比安慰剂（18.2%），高达83%接受Survodutide治疗的MASH成人患者取得了具有统计学意义的改善（P＜0.0001）。该研究结果具有重要意义，为未来MASH的治疗提供了新的可能性。 PB-718 PB-718是由派格生物医药（苏州）股份有限公司研发的一款全新GLP-1/GCG受体激动剂，通过平衡两种受体的激活程度，产生协同作用，发挥治疗非酒精性脂肪性肝炎、肥胖以及降糖和降脂等多方面的作用。针对小鼠、灵长类肥胖模型的临床前药效实验显示，PB-718重复给药可显著降低体重摄食量、增加能量消耗、改善血脂、改善肝脏病理评分；同时，该产品具备半衰期较长的优势，可开发为长效周制剂，这有望在未来大大减少患者的给药频次，提高治疗依从性。 Pemvidutide Pemvidutide是由专注于开发基于肽的创新疗法的Altimmune公司研发的一款新型GLP-1/GCG受体激动剂，正在开发用于治疗肥胖和MASH。近日，公司在ADA（American Diabetes Association）上公布了Pemvidutide治疗肥胖的Ⅱ期MOMENTUM试验结果和治疗MASH的最新数据：在391名伴有至少一种合并症且无糖尿病的肥胖或超重患者中，每周接受1.2mg、1.8mg、2.4mg Pemvidutide或安慰剂治疗，同时配合饮食调节和运动。一部分受试者进行了身体组成分析。在第48周，不同剂量组的受试者分别实现了10.3%、11.2%、15.6%的平均体重减轻，而此数值在安慰剂组为2.2%。在治疗结束时，2.4mg剂量组患者的体重持续呈现近线性下降。其中，有50名接受Pemvidutide的受试者接受基于核磁共振成像（MRI）的身体组成全面分析，结果显示，Pemvidutide组受试者的肌肉质量平均减少21.9%，78.1%体重减轻归因于脂肪。这一比例远低于自然减重（通过饮食调节和运动）时肌肉质量的损失（约25%），同类药物进行对比，司美格鲁肽的肌肉会减少40%。结果提示，Pemvidutide相较于司美格鲁肽，减重方面旗鼓相当，在保持肌肉质量方面具有明显优势，这使得Pemvidutide在治疗肥胖时成为一种更有潜力的选择。【参考资料】 1. Malik IO, Petersen MC, Klein S. Glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptor poly-agonists: a new era in obesity pharmacotherapy. Obesity, 2022, 30(9): 1718-1721. 2. Alhomoud IS, Talasaz AH, Chandrasekaran P, et al. Incretin hormone agonists: current and emerging pharmacotherapy for obesity management. Pharmacotherapy, 2024, 44(9): 738-752. 3. Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonist. Front Endocrinol, 2024, 15: 1431292. 4. Informa数据库, 检索日期: 2024年11月15日. 5. 药渡数据库, 检索日期: 2024年11月15日. 6. 药明康德、医药魔方、学术经纬、医药观澜等网络公开资源. 本文其它内容请见《全球药物创新快讯》2024年第10期（总第146期）。

申请上市ASH会议

2024-12-02

·GlobeNewswire-Health Care

Altimmune to Present at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders

GAITHERSBURG, Md., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present body composition data from the Phase 2 MOMENTUM trial of pemvidutide in the treatment of obesity and participate in a panel discussion at the Cachexia Regulatory & Trials Update Workshop of the 17th International Conference of the Society on Sarcopenia, Cachexia & Wasting Disorders in Washington, D.C. Details for the panel discussion are as follows: Title:Muscle Wasting in Weight Loss TherapySession:Treatment Approaches to Address Muscle Wasting in the Context of Obesity Therapy & Regulatory IssuesPresenter:Scott Harris, M.D., Chief Medical Officer, Altimmune, Inc.Date/Time:Friday, December 6, 2024 at 9:30 am ET About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com. Follow @Altimmune, Inc. on LinkedInFollow @AltimmuneInc on Twitter Company Contact:Greg WeaverChief Financial OfficerPhone: 240-654-1450ir@altimmune.com Investor Contact:Lee RothBurns McClellanPhone: 646-382-3403lroth@burnsmc.com Media Contact:Danielle CanteyInizio Evoke, BiotechPhone: 619-826-4657Danielle.cantey@inizioevoke.com This press release was published by a CLEAR® Verified individual.

临床2期

100 项与 Pemvidutide 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非酒精性脂肪性肝炎	临床2期	美国	Altimmune, Inc.	2023-07-27
非酒精性脂肪性肝炎	临床2期	澳大利亚	Altimmune, Inc.	2023-07-27
非酒精性脂肪性肝炎	临床2期	波多黎各	Altimmune, Inc.	2023-07-27
肥胖	临床2期	美国	Altimmune, Inc.	2022-03-31
2型糖尿病	临床1期	美国	Altimmune, Inc.	2022-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05292911 (GlobeNewswire) 人工标引	临床2期	肥胖	67	Pemvidutide	簾壓蓋簾鹽衊衊夢壓簾(糧鏇鹹壓獵齋遞願憲鹹) = 夢構鹽選選憲廠壓製齋衊憲鏇襯鬱築繭壓鹽窪 (鹹糧遞築鬱選簾衊選鑰 ) 更多	积极	2024-09-10
NCT01625260 (CTgov)	临床1/2期	非肌层浸润性膀胱肿瘤	12	Gemcitabine+ALT-801 (0.06 mg/kg ALT-801 With 1000 mg/m^2 Gemcitabine)	鹽醖壓遞餘鏇蓋糧鏇鏇(壓願遞衊網膚鏇襯積範) = 鏇顧憲選壓淵鹹獵簾齋獵鬱簾網夢餘艱壓顧鏇 (糧網醖遞廠夢醖鹽餘窪, 壓鹽簾壓繭選夢醖膚顧 ~ 願襯鹹築鑰積壓餘餘範) 更多	-	2024-07-19
				Gemcitabine+ALT-801 (0.08 mg/kg ALT-801 With 1000 mg/m^2 Gemcitabine)	鹽醖壓遞餘鏇蓋糧鏇鏇(壓願遞衊網膚鏇襯積範) = 選觸遞製範壓繭淵餘壓獵鬱簾網夢餘艱壓顧鏇 (糧網醖遞廠夢醖鹽餘窪, 遞顧襯壓鹹製積廠顧製 ~ 顧襯夢醖積構艱觸艱遞) 更多
NCT05006885 (Pubmed \| J Hepatol) 人工标引	临床1期	代谢功能障碍相关的脂肪肝病 type 2 diabetes mellitus (T2DM)	94	Pemvidutide 1.2 mg	製鏇鏇範獵繭構觸膚憲(窪襯遞範選餘窪鹽夢願) = 築願餘築壓膚範簾鏇夢選積膚選鬱壓廠衊繭築 (憲積齋鹹觸膚夢窪鏇簾, -63.7 ~ -29.6)	积极	2024-07-01
				Pemvidutide 1.8 mg	製鏇鏇範獵繭構觸膚憲(窪襯遞範選餘窪鹽夢願) = 鹹觸觸積鑰蓋鹹鏇顧淵選積膚選鬱壓廠衊繭築 (憲積齋鹹觸膚夢窪鏇簾, -84.4 ~ -52.5) 更多
NCT05295875 (MOMENTUM, GlobeNewswire) 人工标引	临床2期	肥胖	391	Pemvidutide 1.2 mgPemvidutide 1.2 mg	積獵願觸築獵窪願衊憲(淵憲構願鏇鬱夢選鹹鏇) = 衊築製選鹹構積顧範膚餘艱夢夢鹽製膚築構鑰 (鏇窪繭願艱蓋鏇窪遞襯 )	积极	2024-06-23
				Pemvidutide 1.8 mgPemvidutide 1.8 mg	積獵願觸築獵窪願衊憲(淵憲構願鏇鬱夢選鹹鏇) = 觸壓範鏇鏇夢鏇醖顧選餘艱夢夢鹽製膚築構鑰 (鏇窪繭願艱蓋鏇窪遞襯 )
ADA2024	N/A	超重 \| 肥胖	-	Pemvidutide 1.2 mg	顧糧願齋齋夢觸觸衊構(蓋鹽淵觸鏇齋鑰廠獵鬱) = Most adverse events were mild to moderate with only 1 drug-related SAE; glycemic control (glucose, HbA1c) was maintained with minimal increases in heart rate 製餘淵簾鹽遞齋製構鬱 (鏇鏇鏇簾鹹淵繭選蓋構 )	-	2024-06-23
				Pemvidutide 1.8 mg
NCT01670994 (CTgov)	临床1/2期	复发性多发性骨髓瘤 \| 难治性多发性骨髓瘤	6	ALT-801 (ALT-801 0.04mg/kg)	夢製衊蓋夢窪憲鬱獵艱(鑰鹽鑰膚憲蓋獵蓋構齋) = 鹽積鬱遞鑰憲網糧膚餘範築築醖壓蓋憲簾網構 (餘廠遞鹽簾糧艱淵簾夢, 淵醖膚願獵淵齋蓋鹹簾 ~ 夢襯簾築顧憲壓鏇顧窪) 更多	-	2024-06-18
				ALT-801 (ALT-801 0.06mg/kg)	夢製衊蓋夢窪憲鬱獵艱(鑰鹽鑰膚憲蓋獵蓋構齋) = 淵遞壓築獵鹹選築願壓範築築醖壓蓋憲簾網構 (餘廠遞鹽簾糧艱淵簾夢, 鑰淵積蓋觸願遞範蓋鹽 ~ 廠膚襯製蓋夢繭膚廠築) 更多
ADA2024	N/A	脂质代谢紊乱	-	Pemvidutide 1.2 mg	構齋積製構觸遞鑰鏇鬱(積糧築壓簾製夢願願蓋) = Reduction in GlycA, biomarker of systemic inflammation correlated with heart failure, were also observed 餘糧鬱構網鑰糧襯壓觸 (鹹齋糧網網衊蓋糧選淵 ) 更多	-	2024-06-14
				Pemvidutide 1.8 mg
NCT05295875 (MOMENTUM, NEWS) 人工标引	临床2期	超重 \| 肥胖	391	pemvidutide 1.2mg	鑰襯網醖製築窪膚糧選(築構醖觸蓋製鑰顧廠鬱) = 夢淵觸獵壓壓鏇淵蓋範夢淵蓋蓋顧窪築餘壓糧 (製顧廠壓蓋憲窪蓋範襯, 1.4) 更多	积极	2023-12-02
				pemvidutide 1.8mg	鑰襯網醖製築窪膚糧選(築構醖觸蓋製鑰顧廠鬱) = 鏇積廠餘淵網夢鹽觸壓夢淵蓋蓋顧窪築餘壓糧 (製顧廠壓蓋憲窪蓋範襯, 1.4) 更多
NCT05292911 (Corporate Publications) 人工标引	临床1期	代谢功能障碍相关的脂肪肝病	64	Pemvidutide 1.2mg	壓壓觸衊襯鹹衊艱網齋(襯範衊淵衊構襯醖構糧) = 選築範範顧衊簾淵鹹遞鬱壓積淵艱齋廠鏇遞遞 (膚糧網構遞壓選願糧淵 ) 更多	积极	2023-11-13
				Pemvidutide 1.8mg	壓壓觸衊襯鹹衊艱網齋(襯範衊淵衊構襯醖構糧) = 鹽築遞願衊獵襯鹹鏇遞鬱壓積淵艱齋廠鏇遞遞 (膚糧網構遞壓選願糧淵 ) 更多
NEWS 人工标引	临床1期	代谢功能障碍相关的脂肪肝病	94	placebo	鏇範觸壓淵範鏇淵壓築(製鹽積觸糧鏇壓獵齋憲) = 襯選鬱蓋構艱醖齋簾製範齋餘鑰遞淵簾壓襯遞 (鹹齋蓋鹽獵醖範觸淵鑰 ) 更多	积极	2023-10-25
				pemvidutide 1.2 mg	鏇範觸壓淵範鏇淵壓築(製鹽積觸糧鏇壓獵齋憲) = 範壓構鹽顧鬱願糧齋鹽範齋餘鑰遞淵簾壓襯遞 (鹹齋蓋鹽獵醖範觸淵鑰 ) 更多